Introduction {#sec1-1}
============

Graves\' disease, also known as Parry\'s/Basedow\'s disease, is the most common cause of hyperthyroidism in the world. The prevalence of Graves\' disease is about 0.2% in males and 1.3%--2% in females in the US and UK and ranges from 0.6% to 1.6% in India.\[[@ref1][@ref2][@ref3][@ref4]\] The therapeutic options available for the treatment are antithyroid drugs, radioiodine (^131^I) therapy, and surgery.\[[@ref5]\] Depending on many factors, including socioeconomic and cultural factors, physicians and patients prefer one modality over the other, although all three modalities have been proved to be equally effective. In several parts of the world including the US, radioiodine has become the most commonly used therapeutic modality. The required activity of radioiodine to be administered is calculated using many methods such as gland size, thyroid uptake, and T4 level. However, controversies remain in calculating the correct dose to achieve euthyroidism or hypothyroidism.\[[@ref6][@ref7][@ref8]\] An objective tool to calculate the effective dose is missing. Radioactive iodine uptake (RAIU) test is one such tool used to estimate the dose required and also helps in the differential diagnosis of thyrotoxicosis. It was firmly believed that higher the RAIU, lower is the activity of ^131^I required to administer for successful treatment, as indicated by the following standard formula used to calculate the dose.
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However, recently in a retrospective study from our institute (duration: 1987--2006) made a paradoxical observation that higher the RAIU, higher is the dose required for successful treatment.\[[@ref9]\] Therefore, to address this controversy, we designed a prospective randomized control trail, with 90% power (alpha = 0.05, *n* = 171 in each arm) to test the radioiodine therapy and high-RAIU paradox in patients with Graves\' disease.

Materials and Methods {#sec1-2}
=====================

The current study was approved by the Institutional Ethics Committee. Patients were informed in the local language about the study and consent obtained for participation. All consecutive Graves\' disease patients who were referred for radioiodine therapy were recruited for the study. \[[Chart 1](#F1){ref-type="fig"}\]
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Inclusion and exclusion criteria {#sec2-1}
--------------------------------

Patients clinically and scintigraphically (uniformly increased^99m^ Tc-pertechnetate) diagnosed with Graves\' disease were included in the study. Patients \<18 years of age, pregnant or lactating women, and those with active moderate-to-severe orbitopathy were excluded from the study.

Baseline evaluation {#sec2-2}
-------------------

Prior to radioiodine therapy, all patients underwent detailed clinical and biochemical evaluation. For the clinical assessment, a full-detailed history, prior antithyroid drug treatment or of any other medications, and signs and symptoms of Graves\' disease were evaluated. For biochemical assessment, serum total T3, T4, and thyroid-stimulating hormone (TSH) were measured using radioimmunometric assay.

RAIU measurement {#sec2-3}
----------------

If the patients were on antithyroid drugs, they were asked to stop the drugs for a minimum of 1 week. All patients were administered a standard dose of 5 μCi of ^131^I orally on empty stomach. Patients were asked not to consume food for the next 2 h. RAIU was measured at 2 and 24 h after ^131^I administration. Measurements were done using a standard thyroid uptake probe (Biodex Atomlab 950, Oakville, Ontario, Canada). The uptake was measured with 25--30 cm between the face of the crystal and the anterior neck or phantom. Neck counts, lower thigh counts (body background), counts of a calibrated standard in a neck phantom, and room background counts were obtained at each counting session (in cpm -- counts per minute). RAIU was calculated with the following formula:
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Randomization and radioiodine therapy {#sec2-4}
-------------------------------------

Patients with 24 h RAIU \>50% were block randomized into two groups -- Group 1 patients were administered a fixed activity of 5 mCi (185 MBq) and Group 2 were administered 10 mCi (370 MBq) of ^131^I. Those patients with 24 h RAIU \<50% were excluded from this study. All patients were put on beta blockers or calcium-channel blocker (if beta blockers were contraindicated) for the control of sympathetic symptoms.

Follow-up evaluation {#sec2-5}
--------------------

All patients were reassessed clinically and biochemically (T3, T4, and TSH) 3 months after radioiodine therapy. They were classified into euthyroid, hypothyroid, or persistently toxic states. Hypothyroidism was defined as T3 \<70 ng/dl, T4 \<4.5 μg/dl, and TSH \>4.5 IU/ml. The first-dose cure rate was defined as either euthyroidism or hypothyroidism at 3 months follow-up. Subclinical hyperthyroidism and overt hyperthyroidism were considered as not cured. Patients were then followed up for an average period of 12 months.

Statistical analysis {#sec2-6}
--------------------

Statistical analysis was performed using the SPSS software version 11.5 (SPSS Inc., Chicago, Illinois, USA), and the groups were compared using two-sample Wilcoxon rank-sum (Mann--Whitney) to test the continuous variables. Results were compared using the student paired *t*-test. *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

A total of 415 Graves\' disease patients who fulfilled the inclusion and exclusion criteria were randomized into Group I (*n* = 204) or Group II (*n* = 211). Cent percent recruitment was achieved; however, 71 patients went back to their treating endocrinologist/physician after receiving first dose of ^131^I, and we could not get further information on them in spite of repeated attempt to contact the patients, thus were excluded from the analysis (30 from Group I and 41 from Group II). The final analyses were made on 344 patients (174 in Group I and 170 under Group II) -- 103 males, mean age 38.9 ± 11.18 and 37.6 ± 11.94, mean 24 h RAIU--63.15 ± 10.08 and 66.32 ± 10.71 in Group I and Group II, respectively. Both groups were matching in their baseline characters (age, gender, RAIU, T3, T4, and TSH values). The patients\' characteristics and pretherapy investigation results are shown in [Table 1](#T1){ref-type="table"}. Prior antithyroid drug intake varied from 3 months to 13 years in both the groups (*P* = 0.72).

###### 

Demographic profile of the recruited Graves' disease patients

                                                Group 1 (5 mCi fixed activity)   Group 2 (10 mCi fixed activity)   *P*
  --------------------------------------------- -------------------------------- --------------------------------- -------
  *n*                                           174                              170                               
  Age (mean)                                    38.9±11.18                       37.6±11.94                        0.382
  Females                                       119                              122                               0.495
  Males                                         55                               48                                
  T3 (normal 70-180 ng/ml)                      324.19±126.23                    312.91±141.96                     0.436
  T4 (normal 4.5-12 µg/dl)                      18.63±6.61                       19.09±9.49                        0.612
  TSH (normal 0.5-4.5 mIU/l)                    0.119±0.153                      0.126±0.143                       0.647
  2 h RAIU                                      36.05±17.91                      39.98±19.83                       0.328
  24 h RAIU                                     63.15±10.08                      66.32±10.71                       0.997
  Patients on previous antithyroid medication   143                              142                               0.723

TSH: Thyroid-stimulating hormone, RAIU: Radioiodine uptake, T3: Triiodothyronine, T4: Thyroxine

First-dose overall success rate at the end of 3 months was 237/344 (68.9%); significantly higher (*P* = 0.005) in Group II (76.5% \[*n* = 130\]) as compared to Group I (61.5% \[*n* = 107\]) \[[Figure 1](#F2){ref-type="fig"}\]. In view of persistent hyperthyroidism in 107 patients, additional doses of radioiodine were administered for 67 patients of Group I and 40 of Group II.
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After the second administration of radioiodine, 22 patients (11 patients each in Group I and Group II) went back to their referring endocrinologist/physician for subsequent management and did not report to us, thus considered lost to follow-up. Median total follow-up time was 18 months in Group I and 13 months in Group II. At the time of reporting, there were 59 patients in Group I and 51 in Group II were found euthyroid and 104 and 108 patients were hypothyroid, respectively. No serious adverse effects were reported in any of the patients.

Discussion {#sec1-4}
==========

The optimal and effective administered activity of radioiodine for the successful treatment of Graves\' has been debated over decades. Many tools to estimate the same have been proposed. The important variables noted are thyroid gland volume, thyrotropin receptor antibody level, thyroglobulin level, and radiation-absorbed dose to the thyroid gland. However, the outcome of therapy is not dependent upon any single-measured variable but multiple factors which play role in it.\[[@ref10]\] Another important influencing factor is the length of pretreatment with antithyroid drugs.\[[@ref11][@ref12][@ref13][@ref14]\] In our study, both groups had similar percentage of patients who were on antithyroid medication; hence, interference if any would not be unilateral, ruling out influence on the final outcome. Regarding thyroid gland volume, a factor which has found to have a significant role in predicting the outcome of RAI therapy.\[[@ref15]\] To test this hypothesis, Haase *et al*. divided patients into three groups -- thyroid volume(\<15, 15--25, and \>25 ml) and adjusted administered activity according to volume. The authors reported a significant correlation between thyroid volume and treatment outcome.\[[@ref16]\] However, it is well known that even smaller glands can secrete a high amount of hormones based on the thyrotropin receptor antibody level present and taking only anatomical factor may not give a complete understanding of the disease. Individualized treatment based on target absorbed dose is also proposed rather than administering a fixed dose, but optimum absorbed dose is still debatable, and there is no consensus.\[[@ref17]\] Orsini *et al*. concluded, in their study, that dosimetric approach method based on thyroid-mass reduction instead of a fixed activity or an activity calculated based on a fixed value of the radiation dose to the gland, allows to personalize the ^131^I activity to be administered in patients on an individual basis depending on personal parameter such as thyroid volume and thyroidal iodine kinetics.\[[@ref18]\]

Coming to dosimetry, RAIU value is another factor used to estimate the dose and predict the outcome. There was a strong belief that higher the uptake, lower the dose necessary for successful therapy, with many claiming that high uptake is necessary for better outcome.\[[@ref14]\] However, recently, there have been reports that high-uptake values are predictors of poor outcome\[[@ref19][@ref20]\] including a retrospective analysis done at our institute which showed that 24 h RAIU of more than 50% was associated with higher failure rate.\[[@ref9]\] Hence, it was hypothesized that higher uptake values may demand higher administered activity of ^131^I for successful treatment with single administration.

In this study, we recruited a total of 415 Graves\' patients who had 24 h RAIU \>50% and randomized into two groups. Outcome at the end of first assessment at 3 months showed that higher uptake values were significantly associated with higher failure rates when relatively low amount of radioiodine (5 mCi fixed activity) was administered, and better outcome in high-activity (10 mCi) group which was comparable to other studies in which absorbed dose or thyroid volume was used to estimate the amount of administered activity. It can be argued that higher uptake is because of increased gland volume and so requires higher activity; however, uptake is not just based on the gland volume, rather depends on many factors including thyrotropin receptor-stimulating antibody levels. RAIU is a comprehensive measure of the disease status and may very well correlate with the present state of Graves\' gland and the disease activity, as shown elegantly in this randomized control trial.

Conclusion {#sec1-5}
==========

From this randomized control trial, we conclude that contrary to the belief, the patients of Graves\' disease with higher 24 h RAIU (\>50%) need higher administered activity of radioiodine to cure the disease with the single administered activity of ^131^I. The good old 24h RAIU seems a fairly reliable tool for guiding the administered activity and predicting the outcome of single dose 131I therapy in Graves\' disease patients.
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